Nexstim Plc’s resolutions of the Annual General Meeting of Shareholders
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ), announces that the following resolutions were adopted at its Annual General Meeting of Shareholders held today on 11 May 2021.
1 PRESENTATION OF THE ANNUAL ACCOUNTS AND CONSOLIDATED ACCOUNTS FOR THE YEAR 2020, LOSS FOR THE FINANCIAL YEAR AND DISCHARGE FROM LIABILITY.
The Annual General Meeting of Shareholders adopted the Company s financial statements, including the consolidated financial statements for the year 2020 and resolved that no dividend is paid for the financial year 1 January – 31 December 2020 and that the loss of the financial year is recorded to the retained losses account. The Annual General Meeting discharged the members of the Board of Directors and the Managing Director from liability for the financial year 1 January – 31 December 2020.
Nexstim Oyj: Nexstim Plc s resolutions of the Annual General Meeting of Shareholders
Nexstim Plc s resolutions of the Annual General Meeting of Shareholders
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ), announces that the following resolutions were adopted at its Annual General Meeting of Shareholders held today on 11 May 2021.
1 PRESENTATION OF THE ANNUAL ACCOUNTS AND CONSOLIDATED ACCOUNTS FOR THE YEAR 2020, LOSS FOR THE FINANCIAL YEAR AND DISCHARGE FROM LIABILITY.
The Annual General Meeting of Shareholders adopted the Company s financial statements, including the consolidated financial statements for the year 2020 and resolved that no dividend is paid for the financial year 1 January - 31 December 2020 and that the loss of the financial year is recorded to the retained losses account. The Annual General Meeting discharged the members of the Board of Directors and the Managing Director from liability for the financial year 1 January - 31 December 2020.
Nexstim Oyj: Nexstim Receives a New NBS System Order from a Leading California Based Academic Hospital
Hospital
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received an NBS system order from a distinguished academic hospital based in Northern California, US.
Nexstim NBS systems use the unique SmartFocus TMS technology that enables accurate stimulation of the targeted area in the brain. The Nexstim NBS system is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain.
Mikko Karvinen, CEO of Nexstim, says:
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;